https://atai.life

Home - atai Life SciencesPioneering the development of more effective and potentially disease-modifying mental health treatmentsHome - atai Life Sciences Mission Programs Programs Learn more about our breakthrough programs. Our Programs Scientific Publications People About atai Life Sciences Learn about our team, culture and careers. Our Team Company Values Careers Media Impact Investors Investors Overview News, Events & Presentations Stock Info Corporate Governance SEC Filings Shareholder Services Redefining how the world approaches, prevents, and heals mental health disorders. We are a clinical-stage biopharmaceutical company accelerating the development of highly effective mental health treatments that address the unmet needs of patients. LEARN MORE For everyone, everywhere Led by the brightest minds in the industry atai is home to some of the most sought-after executives and scientists in the space. Equipped with a diverse and dedicated team, we are making a concerted effort to redefine mental health paradigms. Our People Guided by a noble mission We are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. Our Mission Our Programs We have a robust pipeline of development programs and strategic investments across a range of compounds and psychiatric indications. Our Programs Previous Next OUR PERSPECTIVE Shortcomings of existing therapies Current standard of care treatments are ineffective for millions worldwide. Significant burden ~1bn Affected People Global population with mental health disorders >50% Of US population impacted Expected that more than half of US population will have a mental health disorder at some point in their lifetime ~$16tn Global economic impact Estimated global economic costs of mental health disorders by 2030 ~4x Recent impact of COVID-19 Percentage of US adults experiencing symptoms of depression and anxiety rose from 11% in 2019 to 42% end of 2020 Urgent need for innovation ~33% Respond inadequately A third of patients with depression respond inadequately or relapse with current treatments within certain indications Up to 12 wks Slow onset of treatment effect Frontline treatments for depression and anxiety have slow onset (4-12w) ~75% Relapse rate Most of the patients treated for opioid use disorder (OUD) relapse 17 Psychiatry approvals since 2015 Only 17 new drugs approved by the FDA for psychiatry disorders since 2015 – less than 20% relative to oncology (N=107) Our unique approach Compounds with prior evidence in humans To minimize development risk, we focus on compounds that have previously been used in humans and have established safety profiles. Enabling platform technologies Leveraging proprietary technology to accelerate drug discovery, reposition existing molecules with big data approaches, and improve patient outcomes with digital therapeutics. Accelerated drug development By pooling resources and best practices, we aim to responsibly accelerate the development of new medicines to achieve clinically meaningful and sustained behavioral change in mental health patients. Learn more about our approach OUR PROGRAMS News & Insights News atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company… June 26, 2024 7:00 am News atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent,… June 20, 2024 7:00 am News atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company… May 31, 2024 7:00 am JOIN OUR MAILING LIST Sign up to receive the latest news on atai. Email Mission Programs atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, with offices in New York, San Diego and Berlin. Our vision is to heal mental health disorders so that everyone everywhere can live a more fulfilled life. atai Life Sciences N.V. Wallstraße 16 10179 Berlin, Germany Statutory Seat Amsterdam [email protected] People Careers News & Insights Contact Cookies Policy Cookie settings Imprint Privacy Statement © 2024 ATAI LIFE SCIENCES N.V., All Rights Reserved We use cookies in our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of the cookies explicitly. Visit Cookie Settings to know more about the cookies used on our website. Read MoreCookie settings REJECTACCEPT ALLManage consent Close Privacy Overview This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Necessary Necessary Always Enabled Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. CookieDurationDescriptioncookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. Analytics analytics Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc. CookieDurationDescriptionGoogle Analytics1 yearThese cookies are used for tracking the user's behavior on the website to understand the website's performance and reach. Save & Accept Close this module JOIN OUR MAILING LIST Sign up to receive the latest news on atai. Full NameFull NameEmail AddressEnter your email addressSubscribeNo thanks ×enusen-US1729335061https://atai.life

Modifier votre site ?

Que fais-tu?